Especially, despite a lot of effort, the field has yet to pinpoint why and how TMPRSS2-ERG fusion is an early event in prostate cancer development, yet the most significant functions of it seem concentrated in the phase of metastatic disease. The gene discussed is TMPRSS2; the disease is metastatic neoplasm.